Donaldson Capital Management LLC Has $221,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Donaldson Capital Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 443 shares of the medical research company’s stock after selling 272 shares during the period. Donaldson Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $221,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock worth $17,297,426,000 after buying an additional 196,864 shares during the period. Capital World Investors raised its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the period. Geode Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock valued at $4,075,540,000 after buying an additional 197,442 shares during the period. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,149,754,000. Finally, Northern Trust Corp lifted its holdings in Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after acquiring an additional 455,004 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $415.25 on Thursday. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market capitalization of $156.76 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The business’s fifty day moving average is $417.57 and its 200 day moving average is $493.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TMO shares. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Royal Bank of Canada decreased their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Argus cut their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Finally, Citigroup reduced their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.